Added value of angiogenic factors for the prediction of early and late preeclampsia in the first trimester of pregnancy

Fetal Diagnosis and Therapy

Volumn 35, Issue 4, 2014, Pages 258-266

  Crovetto, Francesca ^a,d   Figueras, Francesc ^a   Triunfo, Stefania ^a,e   Crispi, Fatima ^a   Rodriguez Sureda, Victor ^b,c   Peguero, Anna ^a   Dominguez, Carmen ^b,c   Gratacos, Eduard ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSITY OF MILAN   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

Author keywords

First trimester screening; Placental growth factor; Preeclampsia; Soluble endoglin; Soluble Fms like tyrosine kinase 1; Vascular endothelial growth factor

Indexed keywords

ANGIOGENIC FACTOR; ENDOGLIN; PLACENTAL GROWTH FACTOR; SOLUBLE FMS LIKE TYROSINE KINASE RECEPTOR 1; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; FLT1 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; PLACENTA PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; SOLUBLE ENDOGLIN; SOLUBLE FMS LIKE TYROSINE KINASE 1;

ADULT; ARTICLE; BODY MASS; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MEAN ARTERIAL PRESSURE; OUTCOME ASSESSMENT; PREDICTION; PREECLAMPSIA; PRIORITY JOURNAL; UTERINE ARTERY; BLOOD; BLOOD PRESSURE; EARLY DIAGNOSIS; MULTIVARIATE ANALYSIS; PRE-ECLAMPSIA; PREDICTIVE VALUE; PREGNANCY; PREGNANCY OUTCOME; RISK ASSESSMENT; STATISTICAL MODEL; AREA UNDER THE CURVE; CLINICAL ARTICLE;

ADULT; ANTIGENS, CD; BIOLOGICAL MARKERS; BLOOD PRESSURE; CASE-CONTROL STUDIES; COHORT STUDIES; EARLY DIAGNOSIS; FEMALE; HUMANS; LOGISTIC MODELS; MULTIVARIATE ANALYSIS; PRE-ECLAMPSIA; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY PROTEINS; PREGNANCY TRIMESTER, FIRST; RECEPTORS, CELL SURFACE; RISK ASSESSMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84902553894     PISSN: 10153837     EISSN: 14219964     Source Type: Journal    
DOI: 10.1159/000358302     Document Type: Article

References (47)

1. Sibai B, Dekker G, Kupferminc M: Pre-eclampsia. Lancet 2005; 365: 785-799. (Pubitemid 40311367
2. Duley L: The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009; 33: 130-137
3. Conde-Agudelo A, Villar J, Lindheimer M: World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynecol 2004; 104: 1367-1391. (Pubitemid 40458737
4. Forest JC, Charland M, Masse J, et al: Candidate biochemical markers for screening of pre-eclampsia in early pregnancy. Clin Chem Lab Med 2012; 50: 973-984
5. Bujold E, Roberge S, Lacasse Y, et al: Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: A meta-Analysis. Obstet Gynecol 2010; 116: 402-414
6. Roberge S, Villa P, Nicolaides K, et al: Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: A systematic review and meta-Analysis. Fetal Diagn Ther 2012; 31: 141-146
7. Poon LC, Kametas NA, Valencia C, Chelemen T, Nicolaides KH: Hypertensive disorders in pregnancy: Screening by systolic diastolic and mean arterial pressure at 11-13 weeks. Hypertens Pregnancy 2011; 30: 93-107
8. Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH: Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn 2011; 31: 66-74
9. Scazzocchio E, Figueras F, Crispi F, et al: Performance of a first-Trimester screening of preeclampsia in a routine care low-risk setting. Am J Obstet Gynecol 2013; 208: 203.e1-e10
10. Crispi F, Dominguez C, Llurba E, Martin-Gallan P, Cabero L, Gratacos E: Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. Am J Obstet Gynecol 2006; 195: 201-207. (Pubitemid 43927524
11. Llurba E, Carreras E, Gratacos E, Juan M, Astor J, Vives A, Hermosilla E, Calero I, Millan P, Garcia-Valdecasas B, Cabero L: Maternal history and uterine artery Doppler in the assessment of risk for development of early- And late-onset preeclampsia and intrauterine growth restriction. Obstet Gynecol Int 2009; 2009: 275613
12. Cuckle HS: Screening for pre-eclampsia - lessons from aneuploidy screening. Placenta 2011; 32(suppl):S42-S48
13. Poon LC, Karagiannis G, Leal A, Romero XC, Nicolaides KH: Hypertensive disorders in pregnancy: Screening by uterine artery Doppler imaging and blood pressure at 11-13 weeks. Ultrasound Obstet Gynecol 2009; 34: 497-502
14. Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH: Competing risk models in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther 2013; 33: 8-15
15. Parra-Cordero M, Rodrigo R, Barja P, et al: Prediction of early and late pre-eclampsia from maternal characteristics, uterine artery Doppler and markers of vasculogenesis during first trimester of pregnancy. Ultrasound Obstet Gynecol 2013; 41: 538-544
16. Levine RJ, Maynard SE, Qian C, et al: Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-683. (Pubitemid 38364626
17. Maynard S, Epstein FH, Karumanchi SA: Preeclampsia and angiogenic imbalance. Annu Rev Med 2008; 59: 61-78. (Pubitemid 351287924
18. Akolekar R, Zaragoza E, Poon LC, Pepes S, Nicolaides KH: Maternal serum placental growth factor at 11+0 to 13+6 weeks of gestation in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2008; 32: 732-739
19. Erez O, Romero R, Espinoza J, et al: The change in concentrations of angiogenic and anti-Angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med 2008; 21: 279-287. (Pubitemid 351652513
20. Herraiz I, Arbues J, Camano I, Gomez-Montes E, Graneras A, Galindo A: Application of a first-Trimester prediction model for pre-eclampsia based on uterine arteries and maternal history in high-risk pregnancies. Prenat Diagn 2009; 29: 1123-1129
21. Tsatsaris V, Goffin F, Munaut C, et al: Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: Pathophysiological consequences. J Clin Endocrinol Metab 2003; 88: 5555-5563. (Pubitemid 37452769
22. Thadhani R, Mutter WP, Wolf M, et al: Firsttrimester placental growth factor and soluble fms-like tyrosine kinase-1 and risk for preeclampsia. J Clin Endocrinol Metab 2004; 89: 770-775. (Pubitemid 38269892
23. Rana S, Karumanchi SA, Levine RJ, et al: Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 2007; 50: 137-142. (Pubitemid 46986022
24. Wa Law L, Sahota DS, Chan LW, Chen M, Lau TK, Leung TY: Serum placental growth factor and fms-like tyrosine kinase-1 during first trimester in Chinese women with pre-eclampsia - A case-control study. J Matern Fetal Neonatal Med 2011; 24: 808-811
25. McElrath TF, Lim KH, Pare E, et al: Longitudinal evaluation of predictive value for preeclampsia of circulating angiogenic factors through pregnancy. Am J Obstet Gynecol 2012; 207: 407.e1-e7
26. Odibo AO, Rada CC, Cahill AG, et al: Firsttrimester serum soluble fms-like tyrosine kinase-1, free vascular endothelial growth factor, placental growth factor and uterine artery Doppler in preeclampsia. J Perinatol 2013; 33: 670-674
27. Akolekar R, de Cruz J, Foidart JM, Munaut C, Nicolaides KH: Maternal plasma soluble fmslike tyrosine kinase-1 and free vascular endothelial growth factor at 11 to 13 weeks of gestation in preeclampsia. Prenat Diagn 2010; 30: 191-197
28. Baumann MU, Bersinger NA, Mohaupt MG, Raio L, Gerber S, Surbek DV: First-Trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-Trimester markers for late-onset preeclampsia. Am J Obstet Gynecol 2008; 199: 266.e1-e6
29. Youssef A, Righetti F, Morano D, Rizzo N, Farina A: Uterine artery Doppler and biochemical markers (PAPP-A, PIGF, sFlt-1, P-selectin, NGAL) at 11+0 to 13+6 weeks in the prediction of late (>34 weeks) pre-eclampsia. Prenat Diagn 2011; 31: 1141-1146
30. Vatten LJ, Eskild A, Nilsen TI, Jeansson S, Jenum PA, Staff AC: Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet Gynecol 2007; 196: 239.e1-e6
31. Myatt L, Clifton R, Roberts J, et al: Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population?. BJOG 2013; 120: 1183-1191
32. Saxena AR, Seely EW, Rich-Edwards JW, Wilkins-Haug LE, Karumanchi SA, McElrath TF: First-Trimester PAPP-A levels correlate with sFlt-1 levels longitudinally in pregnant women with and without preeclampsia. BMC Pregnancy Childbirth 2013; 13: 85
33. Myatt L, Clifton RG, Roberts JM, et al: Firsttrimester prediction of preeclampsia in nulliparous women at low risk. Obstet Gynecol 2012; 119: 1234-1242
34. Foidart JM, Munaut C, Chantraine F, Akolekar R, Nicolaides KH: Maternal plasma soluble endoglin at 11-13 weeks' gestation in preeclampsia. Ultrasound Obstet Gynecol 2010; 35: 680-687
35. Elhawary TM, El-Bendary AS, Demerdash H: Maternal serum endoglin as an early marker of pre-eclampsia in high-risk patients. Int J Womens Health 2012; 4: 521-525
36. Jelkmann W: Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem 2001; 47: 617-623
37. Robinson HP, Fleming JE: A critical evaluation of sonar 'crown-rump length' measurements. Br J Obstet Gynaecol 1975; 82: 702-710
38. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM: The classification and diagnosis of the hypertensive disorders of pregnancy: Statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001; 20:IX-XIV
39. Figueras F, Meler E, Iraola A, et al: Customized birth weight standards for a Spanish population. Eur J Obstet Gynecol Reprod Biol 2008; 136: 20-24
40. Baschat AA, Gembruch U: The cerebroplacental Doppler ratio revisited. Ultrasound Obstet Gynecol 2003; 21: 124-127. (Pubitemid 36286595
41. Gomez O, Figueras F, Fernandez S, et al: Reference ranges for uterine artery mean pulsatility index at 11-41 weeks of gestation. Ultrasound Obstet Gynecol 2008; 32: 128-132
42. Omron Healthcare: Http://www.omronhealthcare. de/data/catalog/3/554/1/ Validation% 20List%20July-2%202012.pdf
43. Casals E, Aibar C, Martinez JM, et al: Firsttrimester biochemical markers for Down syndrome. Prenat Diagn 1999; 19: 8-11. (Pubitemid 29054594
44. Poon LC, Maiz N, Valencia C, Plasencia W, Nicolaides KH: First-Trimester maternal serum pregnancy-Associated plasma protein-A and pre-eclampsia. Ultrasound Obstet Gynecol 2009; 33: 23-33
45. Biesheuvel CJ, Vergouwe Y, Oudega R, Hoes AW, Grobbee DE, Moons KG: Advantages of the nested case-control design in Diagnostic research. BMC Med Res Methodol 2008; 8: 48
46. Levine RJ, Qian C, Maynard SE, Yu KF, Epstein FH, Karumanchi SA: Serum sFlt1 concentration During preeclampsia and mid-Trimester blood pressure in healthy nulliparous women. Am J Obstet Gynecol 2006; 194: 1034-1041
47. Nicolaides KH: Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn 2011; 31: 7-15.